





Phenacetin-human-HTPBTK-ADMET, RMSLE=0.718 3 factor(Dose) Concentration (mg/L) 3.38 13.5 factor(Route) iv · oral 0.3 -10⁻¹ -0.00 0.10 0.15 0.05 0.20 Time (Days)














Phenacetin-rat-HTPBTK-Consensus, RMSLE=0.454 10² -10factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) iv · oral 10⁻¹ -10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)



















Trichloroethylene-rat-HTPBTK-InVitro, RMSLE=0.744 10 factor(Route) Concentration (mg/L) oral factor(Dose) 7.6 18 10⁻¹ -0.10 0.00 0.05 0.15 Time (Days)































Acrylonitrile-rat-HTPBTK-Consensus, RMSLE=0.345 10² factor(Dose) Concentration (mg/L) 3.4 10 -47 55 84 factor(Route) 1 -10⁻¹ - 0.00 0.01 0.02 0.03 0.04 0.05 Time (Days)





2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-InVitro, RMSLE=0.762 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-ADMET, RMSLE=0.616 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)





2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Consensus, RMSLE=0.997 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)

























Alprazolam-rat-HTPBTK-ADMET, RMSLE=1.8 10 -1 factor(Dose) Concentration (mg/L) 1.25 12.5 factor(Route) · oral 10⁻² -10⁻³ -0.10 0.05 0.15 0.20 0.25 0.00 Time (Days)






















































































1-Naphthalenol, 1-(N-methylcarbamate)-rat-HTPBTK-ADMET, RMSLE=1.95 1 -10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10⁻³ -0.02 0.01 0.03 0.04 Time (Days)











1-Naphthalenol, 1-(N-methylcarbamate)-rat-In Vivo Fits, RMSLE=0.137 10⁻² factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10^{-3} -0.02 0.01 0.03 0.04 Time (Days)


Carbendazim-rat-HTPBTK-InVitro, RMSLE=1.08 10² -10 -Concentration (mg/L) factor(Route) oral factor(Dose) 1000 1 -10⁻¹ -0.0 0.2 0.4 0.6 0.8 Time (Days)








































































































Fenarimol-rat-HTPBTK-Dawson, RMSLE=1.29 1 factor(Dose) Concentration (mg/L) 0.4 2 factor(Route) iv oral 10⁻² -0.1 0.2 0.3 0.4 0.0 0.5 Time (Days)



Fenarimol-rat-In Vivo Fits, RMSLE=0.24 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² 0.2 0.4 0.1 0.3 0.0 0.5 Time (Days)




Formetanate hydrochloride-rat-HTPBTK-ADMET, RMSLE=0.639 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 0 1 3 Time (Days)




Formetanate hydrochloride-rat-HTPBTK-Pradeep, RMSLE=0.904 1 -10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10⁻² -2 3 Time (Days)

Formetanate hydrochloride-rat-HTPBTK-Consensus, RMSLE=0.598 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.03 factor(Route) 10⁻² -· oral 0.003 -2 3 0 1 Time (Days)





Ibuprofen-rat-HTPBTK-InVitro, RMSLE=0.788 10² -10 -Concentration (mg/L) factor(Dose) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)


Ibuprofen-rat-HTPBTK-ADMET, RMSLE=0.791 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)





Ibuprofen-rat-HTPBTK-Pradeep, RMSLE=0.794 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time (Days)








































































Nilvadipine-rat-HTPBTK-InVitro, RMSLE=0.926 10⁻¹ factor(Dose) Concentration (mg/L) 0.1 10 factor(Route) 10⁻² iv · oral 10⁻³ -0.0 0.1 0.2 0.3 0.4 Time (Days)







Nilvadipine-rat-HTPBTK-Pradeep, RMSLE=1.86 10 -1 factor(Dose) Concentration (mg/L) 0.1 10 factor(Route) iv · oral 10⁻² 10⁻³ -0.0 0.1 0.2 0.3 0.4 Time (Days)












Ondansetron-rat-HTPBTK-ADMET, RMSLE=1.08 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)

Ondansetron-rat-HTPBTK-Dawson, RMSLE=1.06 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)





Ondansetron-rat-HTPBTK-Consensus, RMSLE=1.05 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)








Perfluorooctanoic acid-rat-HTPBTK-Consensus, RMSLE=0.948 10³ -10² factor(Dose) 0.2 Concentration (mg/L) 12 10 -40 48 80 320 factor(Route) 1 -· oral 10⁻¹ -0 10 20 40 30 50 Time (Days)















Permethrin-rat-In Vivo Fits, RMSLE=0.29 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.5 0.0 1.0 1.5 2.0 Time (Days)


5,5-Diphenylhydantoin-rat-HTPBTK-InVitro, RMSLE=0.738 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time (Days)














Propamocarb hydrochloride-rat-HTPBTK-InVitro, RMSLE=2.22 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)





Propamocarb hydrochloride-rat-HTPBTK-Dawson, RMSLE=2.42 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-Consensus, RMSLE=2.02 10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)


















































S-Bioallethrin-rat-In Vivo Fits, RMSLE=0.253 0.03 factor(Route) Concentration (mg/L) • oral 10⁻² factor(Dose) 0.8 0.003 -10⁻³ -0.1 0.0 0.2 0.3 Time (Days)











Simazine-rat-In Vivo Fits, RMSLE=0.326 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 10⁻² factor(Route) iv · oral 10⁻³ -0.05 0.10 0.15 0.00 Time (Days)

Tolbutamide-rat-HTPBTK-InVitro, RMSLE=0.243 50 factor(Dose) Concentration (mg/L) 10 20 factor(Route) iv oral 20 -0.0 0.2 0.1 0.3 0.4 0.5 Time (Days)














Tolbutamide-rat-In Vivo Fits, RMSLE=0.0706 10² factor(Dose) Concentration (mg/L) 50 **-**10 20 factor(Route) iv oral 30 -0.2 0.0 0.1 0.3 0.4 0.5 Time (Days)

















Valproic acid-rat-HTPBTK-InVitro, RMSLE=0.61 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.10 0.05 0.00 0.15 Time (Days)

Valproic acid-rat-HTPBTK-Dawson, RMSLE=0.615 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) oral 1 -0.10 0.05 0.00 0.15 Time (Days)



Valproic acid-rat-HTPBTK-OPERA, RMSLE=0.669 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.10 0.05 0.00 0.15 Time (Days)






Potassium perfluorohexanesulfonate-rat-HTPBTK-InVitro, RMSLE=0.724 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) oral 10⁻¹ -0 10 20 40 30 50

Time (Days)

Potassium perfluorohexanesulfonate-rat-HTPBTK-Consensus, RMSLE=0.842



Potassium perfluorohexanesulfonate-rat-In Vivo Fits, RMSLE=0.621 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) · oral 10⁻¹ -0 10 20 40 30 50 Time (Days)


Potassium perfluorobutanesulfonate-rat-HTPBTK-InVitro, RMSLE=0.851 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) 1 -· oral 10⁻¹ -0.5 1.0 1.5 0.0 2.0 Time (Days)


Potassium perfluorobutanesulfonate-rat-HTPBTK-Consensus, RMSLE=0.847 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) 1 -· oral 10⁻¹ -0.5 1.0 0.0 1.5 2.0 Time (Days)

Potassium perfluorobutanesulfonate-rat-In Vivo Fits, RMSLE=0.496 10² factor(Dose) 10-Concentration (mg/L) 20 100 factor(Route) · oral 10⁻¹ -0.5 1.0 1.5 0.0 2.0 Time (Days)


Perfluorohexanoic acid-rat-HTPBTK-InVitro, RMSLE=1.48 10² factor(Dose) 10 -Concentration (mg/L) 40 80 160 factor(Route) 1 -· oral 10⁻¹ -0.50 0.00 0.25 0.75 1.00 Time (Days)


Perfluorohexanoic acid-rat-HTPBTK-Consensus, RMSLE=1.47 10² factor(Dose) 10 **-**Concentration (mg/L) 40 80 160 factor(Route) · oral 10⁻¹ -0.50 0.00 0.25 0.75 1.00 Time (Days)








Perfluorodecanoic acid-rat-HTPBTK-Consensus, RMSLE=0.486 10² factor(Dose) 10 -Concentration (mg/L) 2 10 20 factor(Route) · oral 1 -10⁻¹ -0 50 100 Time (Days)



















Oxazepam-rat-HTPBTK-Consensus, RMSLE=1.08 10² factor(Dose) 20 Concentration (mg/L) 50 10 **-**200 400 factor(Route) · oral 1 -0.0 0.3 0.6 0.9 Time (Days)

Oxazepam-rat-In Vivo Fits, RMSLE=0.234 10factor(Dose) 20 Concentration (mg/L) 3 -50 200 400 factor(Route) · oral 1 -0.3 -0.0 0.3 0.6 0.9 Time (Days)

Pentachlorophenol-rat-HTPBTK-InVitro, RMSLE=0.738 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.0 0.5 1.0 1.5 Time (Days)




Pentachlorophenol-rat-HTPBTK-Pradeep, RMSLE=0.741 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.0 0.5 1.0 1.5 Time (Days)




Pentachlorophenol-rat-In Vivo Fits, RMSLE=0.293 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.0 0.5 1.0 1.5 Time (Days)

Gemfibrozil-rat-HTPBTK-InVitro, RMSLE=0.828 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.50 0.00 0.25 0.75 1.00 Time (Days)




Gemfibrozil-rat-HTPBTK-Dawson, RMSLE=0.712 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time (Days)




Gemfibrozil-rat-HTPBTK-Consensus, RMSLE=0.823 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.50 0.00 0.25 0.75 1.00 Time (Days)


Gemfibrozil-rat-In Vivo Fits, RMSLE=0.335 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time (Days)





Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-Dawson, RMSLE=0.484 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv 1 -0.006 0.009 0.012 0.003 Time (Days)


Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-Consensus, RMSLE=0.475 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv iv 1 -0.006 0.009 0.012 0.003 Time (Days)


















Benzophenone-rat-HTPBTK-Consensus, RMSLE=0.733 1 factor(Dose) Concentration (mg/L) 2.5 10 factor(Route) oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)

Benzophenone-rat-In Vivo Fits, RMSLE=0.323 1 factor(Dose) Concentration (mg/L) 2.5 10 10⁻¹ factor(Route) oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-InVitro, RMSLE=2.78 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² 0.2 0.0 0.4 0.6

Time (Days)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-ADMET, RMSLE=2.3




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Dawson, RMSLE=2.57 10² factor(Dose) 8 100 250 500





2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Consensus, RMSLE=2.44 10² -





2-Hydroxy-4-methoxybenzophenone-rat-In Vivo Fits, RMSLE=0.391 10 -1 factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) · oral 10⁻² -0.2 0.6 0.0 0.4 Time (Days)
















Phenolphthalein-rat-In Vivo Fits, RMSLE=0.386 10² -10 -Concentration (mg/L) factor(Dose) 25 factor(Route) 1 -- iv 10⁻¹ -10⁻² 0.25 0.50 0.75 0.00 1.00 Time (Days)
















Tamoxifen-rat-HTPBTK-InVitro, RMSLE=1.58 0.3 -10⁻¹ factor(Route) Concentration (mg/L) **→** oral 0.03 factor(Dose) 0.33 0.344 0.411 10⁻² -0.003 -0.2 0.6 0.0 0.4 Time (Days)





Tamoxifen-rat-HTPBTK-Dawson, RMSLE=0.864 10⁻¹ -0.03 factor(Route) Concentration (mg/L) oral factor(Dose) 0.33 10⁻² -0.344 0.411 0.003 -0.2 0.0 0.4 0.6 Time (Days)


Tamoxifen-rat-HTPBTK-Pradeep, RMSLE=0.915 10⁻¹ -0.03 factor(Route) Concentration (mg/L) ► oral factor(Dose) 0.33 10⁻² -0.344 0.411 0.003 -0.2 0.4 0.6 0.0 Time (Days)


Tamoxifen-rat-HTPBTK-Consensus, RMSLE=1.12 10⁻¹ factor(Route) Concentration (mg/L) **→** oral 0.03 factor(Dose) 0.33 0.344 0.411 10⁻² -0.003 -0.2 0.4 0.6 0.0 Time (Days)











































Novaluron-rat-In Vivo Fits, RMSLE=0.173 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² -0.003 -0 2 3 Time (Days)







































2-Methylimidazole-rat-HTPBTK-OPERA, RMSLE=0.988 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time (Days)


2-Methylimidazole-rat-HTPBTK-Consensus, RMSLE=1.34 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time (Days)


















Dichloroacetic acid-rat-HTPBTK-ADMET, RMSLE=0.744 10² factor(Route) 10-Concentration (mg/L) · oral factor(Dose) 10 40 60 100 1 -10⁻¹ 0.0 0.1 0.2 0.3 Time (Days)



Dichloroacetic acid-rat-HTPBTK-Consensus, RMSLE=0.846 10 factor(Route) Concentration (mg/L) · oral factor(Dose) 10 40 60 1 -100 10⁻¹ -0.2 0.0 0.1 0.3 Time (Days)

Dichloroacetic acid-rat-In Vivo Fits, RMSLE=0.375 30 -10factor(Route) Concentration (mg/L) · oral 3 factor(Dose) 10 40 60 1 -100 0.3 -0.1 0.2 0.0 0.3 Time (Days)


Dibromoacetic acid-rat-HTPBTK-ADMET, RMSLE=0.804 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)

Dibromoacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.554 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)

Dibromoacetic acid-rat-HTPBTK-Consensus, RMSLE=0.502 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.2 0.0 0.1 0.3 Time (Days)


Dibromoacetic acid-rat-In Vivo Fits, RMSLE=0.337 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 -· oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)

Bromochloroacetic acid-rat-HTPBTK-ADMET, RMSLE=1.01 10² -10factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) 1 oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)




Bromochloroacetic acid-rat-HTPBTK-Consensus, RMSLE=0.676 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)

Bromochloroacetic acid-rat-In Vivo Fits, RMSLE=0.386 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)





Isoeugenol-rat-HTPBTK-Dawson, RMSLE=1.73 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -10⁻² 0.0 0.1 0.2 0.3 0.4 Time (Days)





Isoeugenol-rat-HTPBTK-Consensus, RMSLE=1.18 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -0.0 0.1 0.3 0.2 0.4 Time (Days)


Isoeugenol-rat-In Vivo Fits, RMSLE=0.36 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) · oral 10⁻¹ -0.0 0.1 0.2 0.3 0.4 Time (Days)












Emodin-rat-In Vivo Fits, RMSLE=0.189 10factor(Dose) Concentration (mg/L) 5 40 80 1 factor(Route) · oral 10⁻¹ -0.2 0.1 0.3 0.4 0.5 0.0 Time (Days)


Anthraquinone-rat-HTPBTK-ADMET, RMSLE=1.78 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)


Anthraquinone-rat-HTPBTK-Dawson, RMSLE=1.56 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)


Anthraquinone-rat-HTPBTK-OPERA, RMSLE=1.58 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ 0.25 0.50 0.75 0.00 1.00 Time (Days)


Anthraquinone-rat-HTPBTK-Consensus, RMSLE=1.48 10² -10factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)





















































C.I. Solvent Red 1-rat-HTPBTK-Consensus, RMSLE=1.49 10-1 -Concentration (mg/L) factor(Route) ⊢ oral 10⁻¹ factor(Dose) 20 10⁻² -10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)





Diclofenac-rat-HTPBTK-OPERA, RMSLE=0.564 10² -30 factor(Dose) Concentration (mg/L) 18 60 factor(Route) 10 iv · oral 3 -0.1 0.2 0.0 0.3 Time (Days)

Diclofenac-rat-HTPBTK-Consensus, RMSLE=0.56 10² -30 factor(Dose) Concentration (mg/L) 18 60 factor(Route) 10 iv · oral 3 -0.1 0.2 0.0 0.3 Time (Days)














Diltiazem-rat-In Vivo Fits, RMSLE=0.147 10 -1 -Concentration (mg/L) factor(Route) · oral factor(Dose) 20 10⁻¹ -0.2 0.0 0.1 0.3 0.4 Time (Days)































Bis(2-chloroethoxy)methane-rat-HTPBTK-Consensus, RMSLE=0.396 10 factor(Dose) Concentration (mg/L) 20 40 factor(Route) 10⁻¹ -10⁻² -0.3 0.2 0.4 0.0 0.1 Time (Days)




Thiodiglycolic acid-rat-HTPBTK-OPERA, RMSLE=1.03 30 -10-Concentration (mg/L) factor(Dose) 20 3 factor(Route) iv iv 1 -0.3 -0.0 0.1 0.2 0.3 0.4 Time (Days)


Thiodiglycolic acid-rat-HTPBTK-Consensus, RMSLE=0.391 30 -10 -Concentration (mg/L) factor(Dose) 20 3 factor(Route) iv 1 -0.3 -0.0 0.2 0.3 0.1 0.4 Time (Days)




Oxoacetic acid--water (1/1)-rat-HTPBTK-OPERA, RMSLE=0.708 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)


Oxoacetic acid--water (1/1)-rat-HTPBTK-Consensus, RMSLE=0.708 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)








2-Methyltetrahydrofuran-rat-HTPBTK-Consensus, RMSLE=0.717 10² factor(Dose) 10 -2.5 10 Concentration (mg/L) 30 40 100 400 factor(Route) oral 10⁻¹ -10⁻² -0.1 0.2 0.3 0.4 0.0 0.5 Time (Days)

















3,3',4,4',5-Pentachlorobiphenyl-rat-HTPBTK-OPERA, RMSLE=0.741 3e-04 -10⁻⁴ factor(Dose) Concentration (mg/L) 1e-05 0.001 factor(Route) ⊢ oral 3e-05 -10⁻⁵ -300 Ó 100 200 Time (Days)

 $3,3',4,4',5-Pentachlorobiphenyl-rat-HTPBTK-Consensus,\ RMSLE=0.819$ 3e-04 **-**10⁻⁴ factor(Dose) Concentration (mg/L) 1e-05 0.001 factor(Route) - oral 3e-05 **-**10⁻⁵ -300 Ó 100 200 Time (Days)

Perfluorooctanesulfonate-rat-HTPBTK-Consensus, RMSLE=0.618 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 1 -2 20 10⁻¹ -0 50 100 Time (Days)







Hexachlorobenzene-rat-In Vivo Fits, RMSLE=0.176 10-1 factor(Route) Concentration (mg/L) · oral factor(Dose) 10⁻¹ 0.03 0.1 0.3 30 10⁻² -10⁻³ -20 40 60 80 Ö Time (Days)

